SignalXSignalX

PTCT PTC THERAPEUTICS, INC.

Q3 2025 10-Q
Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
PTC THERAPEUTICS, INC. Overview

PTC THERAPEUTICS, INC. (PTCT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New director/officer trading arrangements under Rule 10b5-1 adopted Sept 2025 for sales up to 259,346 shares, latest expiring March 2027
  • • Updated insider trading compliance risk reflecting expanded use of Rule 10b5-1 plans to manage equity sales and tax obligations
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$211M

Net Income

$16M

Operating Margin

1.4%

Net Margin

7.5%

ROE

-10.2%

Total Assets

$2.6B

Source: XBRL data from PTC THERAPEUTICS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on PTC THERAPEUTICS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.